Antiangiogenic antithrombin down-regulates the expression of the proangiogenic heparan sulfate proteoglycan, perlecan, in endothelial cells

Blood

Volumn 103, Issue 4, 2004, Pages 1185-1191

  Zhang, Weiqing ^b   Chuang, Yung Jen ^b   Swanson, Richard ^b   Li, Juan ^b   Seo, Kyunga ^b   Leung, Lawrence ^b   Lau, Lester F ^b   Olson, Steven T ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BASIC FIBROBLAST GROWTH FACTOR; PERLECAN; PROTEOHEPARAN SULFATE; SERINE PROTEINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA1;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD CLOTTING; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; DNA MICROARRAY; ENDOTHELIUM CELL; HEATING; HUMAN; HUMAN CELL; HUMAN UMBILICAL VEIN ENDOTHELIUM CELL; IMMUNOBLOTTING; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0842264049     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-08-2920     Document Type: Article

References (42)

1. Björk I, Olson ST. Antithrombin, a bloody important serpin. In: Church FC, Cunningham DD, Ginsburg D, Hoffman M, Stone SR, Tollefsen DM, eds. Chemistry and Biology of Serpins. New York, NY: Plenum Press; 1997:17-33.
2. Gettins PGW. Serpin structure, mechanism, and function. Chem Rev. 2002;102:4751-4803.
3. Olson ST, Björk I, Bock SC. Identification of critical molecular interactions mediating heparin activation of antithrombin: implications for the design of improved heparin anticoagulants. Trends Cardiovasc Med. 2002;12:198-205.
4. Olson ST, Chuang Y-J. Heparin activates antithrombin anticoagulant function by generating new interaction sites (exosites) for blood clotting proteinases. Trends Cardiovasc Med. 2002;12:331-338.
5. Oelschläger C, Römisch J, Staubitz A, et al. Antithrombin III inhibits nuclear factor κB activation in human monocytes and vascular endothelial cells. Blood. 2002;99:4015-4020.
6. Geiben-Lynn R, Brown N, Walker BD, Luster AD. Purification of a modified form of bovine antithrombin III as an HIV-1 CD8+ T-cell antiviral factor. J Biol Chem. 2002;277:42352-42357.
7. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science. 1999;285:1926-1928.
8. Larsson H, Sjöblom T, Dixelius J, et al. Antiangiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells. Cancer Res. 2000;60:6723-6729.
9. Larsson H, Åkerud P, Nordling K, Raub-Segall E, Claesson-Welsh L, Björk I. A novel anti-angiogenic form of antithrombin with retained proteinase binding ability and heparin affinity. J Biol Chem. 2001;276:11996-12002.
10. Kisker O, Onizuka S, Banyard J, et al. Generation of multiple angiogenesis inhibitors by human pancreatic cancer. Cancer Res. 2001;61:7298-7304.
11. Mourey L, Samama JP, Delarue M, Petitou M, Choay J, Moras D. Crystal structure of cleaved bovine antithrobin III at 3.2 Å resolution. J Mol Biol. 1993;232:223-241.
12. Skinner R, Abrahams J-P, Whisstock JC, Lesk AM, Carrell RW, Wardell MR. The 2.6 Å structure of antithrombin indicates a conformational change at the heparin binding site. J Mol Biol. 1997;266:601-609.
13. Wardell MR, Chang WSW, Bruce D, Skinner R, Lesk AM, Carrell RW. Preparative induction and characterization of L-antithrombin: a structural homologue of latent plasminogen activator inhibitor-1. Biochemistry. 1997;36:13133-13142.
14. Björk I, Fish WW, Production in vitro and properties of a modified form of bovine antithrombin, cleaved at the active site by thrombin. J Biol Chem. 1982;257:9487-9493.
15. Chang W, Wardell M, Lomas D, Carrell R. Probing serpin reactive-loop conformations by proteolytic cleavage. Biochem J. 1996;314:647-653.
16. Stratikos E, Gettins PGW. Formation of the covalent serpin-proteinase complex involves translocation of the proteinase by more than 70 Å and full insertion of the reactive center loop into β-sheet A. Proc Natl Acad Sci U S A. 1999;96:4808-4813.
17. Huntington JA, Read RJ, Carrell RW. Structure of a serpin-protease complex shows inhibition by deformation. Nature. 2000;407:923-926.
18. Marciniak E. Thrombin-induced proteolysis of human antithrombin III: an outstanding contribution of heparin. Br J Haematol. 1981;48:325-336.
19. Zhou A, Huntington JA, Carrell RW. Formation of the antithrombin heterodimer in vivo and the onset of thrombosis. Blood. 1999;94:3388-3396.
20. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9:653-660.
21. Pollack JR, Perou CM, Alizadeh AA, et al. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet. 1999;23:41-46.
22. Aviezer D, Hecht D, Safran M, Eisinger M, David G, Yayon A, Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell. 1994;79:1005-1013.
23. Aviezer D, Iozzo RV, Noonan DM, Yayon A. Suppression of autocrine and paracrine functions of basic fibroblast growth factor by stable expression of perlecan antisense cDNA. Mol Cell Biol. 1997;17:1938-1946.
24. Olson ST, Björk I, Shore JD. Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin. Methods Enzymol. 1993;222:525-560.
25. Olson ST. Heparin and ionic strength-dependent conversion of antithrombin III from an inhibitor to a substrate of alpha-thrombin. J Biol Chem. 1985;260:10153-10160.
26. Arocas V, Bock SC, Raja SM, Olson ST, Björk I. Lysine 114 of antithrombin is of crucial importance for the affinity and kinetics of heparin pentasaccharide binding. J Biol Chem. 2001;276:43809-43817.
27. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J Clin Invest. 1973;52:2745-2756.
28. St. Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science. 2000;289:1197-1202.
29. Gollub J, Ball CA, Binkley G, et al. The Stanford Microarray Database: data access and quality assessment tools. Nucleic Acids Res. 2003;31:94-96.
30. 1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem. 2002;277:16464-16469.
31. Murdoch AD, Dodge GR, Cohen I, Tuan RS, Iozzo RV. Primary structure of the human heparan sulfate proteoglycan from basement membrane (HSPG2/perlecan): a chimeric molecule with multiple domains homologous to the low density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth factor. J Biol Chem. 1992;267:8544-8557.
32. Towbin H, Gordon J. Immunoblotting and dot immunobinding: current status and outlook. J Immunol Methods. 1984;72:313-340.
33. Iozzo RV, San Antonio JD. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest. 2001;108:349-355.
34. Kaji T, Yamada A, Miyajima S, et al. Cell-density-dependent regulation of proteoglycan synthesis by transforming growth factor-β1 in cultured bovine aortic endothelial cells. J Biol Chem. 2000;275:1463-1470.
35. Sharma B, Handler M, Eichstetter I, Whitelock JM, Nugent MA, Iozzo RV. Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Invest. 1998;102:1599-1608.
36. Adatia R, Albini A, Carlone S, et al. Suppression of invasive behavior of melanoma cells by stable expression of anti-sense perlecan cDNA. Ann Oncol. 1997;8:1257-1261.
37. Costell M, Gustafsson E, Aszodi A, et al. Perlecan maintains the integrity of cartilage and some basement membranes. J Cell Biol. 1999;147:1109-1122.
38. Ankawa-Hirasawa E, Watanabe H, Takami H, Hassell JR, Yamada Y. Perlecan is essential for cartilage and cephalic development. Nat Genet. 1999;23:354-358.
39. Sasaki T, Larsson H, Kreuger J, et al. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin. EMBO J. 1999;18:6240-6248.
40. Kreuger J, Matsumoto T, Vanwildemeersch M, et al. Role of heparan sulfate domain organization in endostatin inhibition of endothelial cell function. EMBO J. 2002;21:6303-6311.
41. Olson ST, Björk I, Sheffer R, Craig PA, Shore, JD, Choay J. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions: resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem. 1992;267:12528-12538.
42. Mertens G, Cassiman JJ, Van Den Berghe H, Vermylen J, David G. Cell surface heparan sulfate proteoglycans from human vascular endothelial cells: core protein characterization and antithrombin III binding properties. J Biol Chem. 1992;267:20435-20443.